A robust genomic-based prognostic model for the assessment of cancer stemness and survival for patients with hepatocellular carcinoma
Cheng-Li Du a , Shen-Yu Wei b , Yun-Hao Chen a , Kang-Jie Chen c , ∗
a Division of Thoracic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
b Zhejiang University School of Medicine, Hangzhou 310003, China
c Division of Hepatobiliary Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Abstract：Hepatocellular carcinoma (HCC) is an aggressive malignancy with poor long-term prognosis [1] . Liver cancer stem cell (CSC) can drive the metastasis, drug resistance, and recurrence of HCC [2] . The regulatory mechanisms about liver cancer stemness have been investigated, which encouraged the identification and characterization of novel prognostic and therapeutic strategies for HCC [3] . As genome-wide, high-throughput sequencing became available, some prognostic models have been established based on gene expression profiles associated with HCC stemness [4] . Nevertheless, in most cases, these models were hardly used in clinical practice due to complex algorithm and expensiveness. This study aimed to establish a stable stemness-related clinical prediction model with simplified algorithms based on gene expression profiles. Furthermore, biomolecular experiments were performed to examine the oncogenic functions of stemness-related genes.
引用本文:
. [J]. Hepatobiliary Pancreat Dis Int, 2024, 23(1): 97-102.
Du CL, Wei SY, Chen YH, Chen KJ. A robust genomic-based prognostic model for the assessment of cancer stemness and survival for patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2024, 23(1): 97-102.
2024, Vol. 23 
